918博天堂(中国)有限公司官网918博天堂

March 2020


BioNTech and Fosun Pharma announced their strategic collaboration on the development of mRNA vaccine. Fosun Pharma has been licensed by BioNTech to exclusively develop and commercialize COVID-19 vaccines based on its mRNA technology platform on the Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region.

November 2020

Fosun Pharma initiated the Phase II clinical trial of BNT162b2 in China

July 2020

Fosun Pharma initiated the Phase I clinical trial of BNT162b1 in China.

January 2021

BNT162b2 received Authorization for Emergency Use in Hong Kong SAR

February 2021

BNT162b2 received the Special Import Authorization in Macau SAR

September 2021

BNT162b2 started to be vaccinated in Taiwan region

March 2021

BNT162b2 was used in the local COVID-19 vaccination program in Hong Kong SAR and Macau SAR

February 2022

Over 20 million doses of BNT162b2 have been administered in Hong Kong SAR, Macau SAR and Taiwan region

For more information on mRNA vaccines, please visit the official website of BioNTech:

918博天堂